Which funds are similar to HDFC Pharma And Healthcare Fund Direct-Growth?
Funds similar to HDFC Pharma And Healthcare Fund Direct-Growth in the Equity: Sectoral-Pharma category include Nippon India Pharma Fund Direct-Growth, ICICI Prudential Healthcare Fund Direct-Growth, and SBI Healthcare Opportunities Fund Direct Plan-Growth. These funds follow a comparable investment mandate and are benchmarked against similar indices. You can compare them in detail — across returns, risk metrics, expense ratio, and portfolio composition — using the fund comparison tool on sharpely.
What is the rank of HDFC Pharma And Healthcare Fund Direct-Growth in its category?
On a 3-year return basis HDFC Pharma And Healthcare Fund Direct-Growth is ranked 1 out of 12 funds in the Equity: Sectoral-Pharma category as of 21 Oct 2026. Consistently ranking in the top across multiple time periods is a stronger signal of fund quality than a single-period rank.
How does HDFC Pharma And Healthcare Fund Direct-Growth's expense ratio compare to similar funds?
HDFC Pharma And Healthcare Fund Direct-Growth has an expense ratio of 1.05%. The peers Nippon India Pharma Fund Direct-Growth has an expense ratio of 0.99% and ICICI Prudential Healthcare Fund Direct-Growth has 1.32%. Over the long term, a higher expense ratio can meaningfully drag on returns, so it is worth evaluating whether the fund's performance justifies the additional cost.
How does HDFC Pharma And Healthcare Fund Direct-Growth's AUM compare to similar funds?
HDFC Pharma And Healthcare Fund Direct-Growth has an AUM of ₹3,501.37 crore. The peers Nippon India Pharma Fund Direct-Growth has an AUM of ₹9,166.4 crore and ICICI Prudential Healthcare Fund Direct-Growth has ₹6,861.2 crore. A large AUM can sometimes limit a fund's ability to take meaningful positions in mid and small-cap stocks, as larger trades can move prices. This is particularly relevant for funds that invest outside large caps.
Which fund has the best 3-year returns in the Equity: Sectoral-Pharma?
The top performing fund in the Equity: Sectoral-Pharma category on a 3-year basis is SBI Healthcare Opportunities Fund Direct Plan-Growth with a CAGR of 21.46% as of 21 Oct 2026. HDFC Pharma And Healthcare Fund Direct-Growth has delivered 27.69% CAGR over the same period, ranking 1 out of 12 funds. You can view and compare the full category ranking on sharpely.
How does HDFC Pharma And Healthcare Fund Direct-Growth rank in risk-adjusted returns vs peers?
The Sharpe ratio of HDFC Pharma And Healthcare Fund Direct-Growth is shown in the Alpha, Beta & Sharpe section on the Performance tab.
